Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AHCO vs BBNX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AHCO Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)
AHCO Overall Winner
6-Pillar Tally: AHCO 6 – 0 BBNX
Matrix Metrics: AHCO 7 – 3 BBNX
As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over Beta Bionics, Inc. (BBNX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas BBNX carries 52.1/100 (HOLD) at $13.36 (N/M Forward P/E, -72.8% operating margin).
- Composite vs. Pillar Nuance: While BBNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. AHCO 45.2/100 HOLD), AHCO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (3.8% vs. -72.8% operating margin) and revenue trajectory (+10.9% vs. +30.3% YoY).
- Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile BBNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About AHCO vs BBNX
AHCO
Head-to-Head Winner
AdaptHealth Corp. Common Stock
$7.20
-0.69% 1D
Market Cap
$989.8M
TTM Revenue
$3.44B
Forward P/E
7.8x
Beta / 30D Vol
0.17β · 67% Vol
Unified Composite Score
45.2
HOLD
Tech 29.0
Fund 46.0
Flow 54.0
Mom 60.0
Weinstein Technical Phase
Markup · Hold / add on dips
BBNX
Beta Bionics, Inc. Common Stock
$13.36
+0.3% 1D
Market Cap
$724.2M
TTM Revenue
$127M
Forward P/E
N/M
Beta / 30D Vol
1.75β · 104% Vol
Unified Composite Score
52.1
HOLD
Tech 50.0
Fund 53.0
Flow 69.0
Mom 68.9
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (AHCO 6 – 0 BBNX)
1. Valuation Multiples
AHCO
Forward P/E
7.8x
N/M
Trailing P/E
7.8x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
0.9x
5.1x
2. Growth & Scale
AHCO
Revenue Growth (YoY)
+10.9%
+30.3%
Earnings Growth (YoY)
+6.7%
+0.0%
TTM Revenue (USD)
$3.44B
$127M
Market Cap
$989.8M
$724.2M
3. Profitability & Quality
AHCO
Gross Margin
18.2%
58.6%
Operating Margin
3.8%
-72.8%
Net Profit Margin
-11.8%
-65.3%
Return on Equity (ROE)
-28.4%
-23.9%
4. Balance Sheet & Cash Flow
AHCO
Cash Generation (TTM)
$82M
-$66M
Cash Flow Margin
2.4%
-51.8%
Net Cash / Leverage
$1.97B Net Debt (1.67x D/E)
$75M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
AHCO
Options Structure Phase
SURGE
CONSOLIDATION
Current IV / %ile
66.9% (12th %ile)
0.0% (<1st %ile)
Put/Call OI Skew
N/A
0.01x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markup
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
AHCO
OpEx & R&D Intensity
14.4% of Rev ($495M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: AHCO (7) vs BBNX (3)| Institutional Metric | AHCO | BBNX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $989.8M | $724.2M | AHCO | |
| Trailing P/E Ratio | 7.8x | N/M | AHCO | |
| Forward P/E Ratio | 7.8x | N/M | AHCO | |
| Revenue Growth (YoY) | +10.9% | +30.3% | BBNX | |
| Operating Margin (TTM) | 3.8% | -72.8% | AHCO | |
| Net Profit Margin | -11.8% | -65.3% | AHCO | |
| Return on Equity (ROE) | -28.4% | -23.9% | BBNX | |
| 52-Week Range Position | 24% ($5–$13) | 19% ($9–$33) | AHCO | |
| Beta / 30D Volatility | 0.17β · 67% Vol | 1.75β · 104% Vol | AHCO | |
| Unified Institutional Score | 45.2 / 100 (HOLD) | 52.1 / 100 (HOLD) | BBNX | |
| Trailing 12M Revenue (USD) | $3.44B | $127M | Scale | |
| Gross Profit Margin (TTM) | 18.2% | 58.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.9x EV/Rev | N/M PEG · 5.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $82M ($1.97B Net Debt (1.67x D/E)) | -$66M ($75M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
AHCO +47.61 pp
3M Horizon
AHCO +60.18 pp
6M Horizon
BBNX +44.13 pp
1Y Horizon
AHCO +30.92 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | AHCO Revenue | BBNX Revenue | AHCO Op. Margin | BBNX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $350M | N/A | 9.0% | N/A | AHCO |
| FY2019 | $530M | N/A | 5.5% | N/A | AHCO |
| FY2020 | $1.06B | N/A | 6.8% | N/A | AHCO |
| FY2021 | $2.45B | N/A | 9.2% | N/A | AHCO |
| FY2022 | $2.97B | N/A | 6.4% | N/A | AHCO |
| FY2023 | $3.20B | $10M | -18.7% | -298.9% | AHCO |
| FY2024 | $3.26B | $70M | 8.1% | -69.5% | AHCO |
| FY2025 | $3.24B | $100M | 2.8% | -71.5% | AHCO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
AHCO
SURGE
Current IV
66.9%
IV Percentile
12th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BBNX
CONSOLIDATION
Current IV
0.0%
IV Percentile
<1st %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact BBNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
AHCO Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
14.4% of Rev ($495M)
90D Engineering Disclosures
0 Published
BBNX Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ AHCO vs BBNX Key Questions & Quantitative Answers
As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over Beta Bionics, Inc. (BBNX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas BBNX carries 52.1/100 (HOLD) at $13.36 (N/M Forward P/E, -72.8% operating margin). Composite vs. Pillar Nuance: While BBNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. AHCO 45.2/100 HOLD), AHCO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (3.8% vs. -72.8% operating margin) and revenue trajectory (+10.9% vs. +30.3% YoY). Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile BBNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AHCO leads the Growth & Scale pillar: AHCO posts +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin), compared with BBNX at +30.3% YoY revenue growth and +0.0% YoY earnings growth on $127M TTM revenue (58.6% gross margin, -72.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AHCO cumulative revenue shifted +825.7% while BBNX shifted +900.0%. In operating R&D and SG&A reinvestment, AHCO deploys 14.4% of Rev ($495M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BBNX.
AHCO screens cheaper on headline valuation multiples. AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin), whereas BBNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.1x EV/Revenue (-51.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHCO (-28.4% ROE) versus BBNX (-23.9% ROE) capital efficiency.
In options market volatility and institutional positioning, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk). By comparison, BBNX carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.75β · 104% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BBNX vs AHCO · Reverse Pair
AHCO vs OPCH
· Sector Peer
AHCO vs ADUS
· Sector Peer
AHCO vs RPAY
· Sector Peer
BBNX vs KMTS
· Sector Peer
BBNX vs CBLL
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem